# Unicellab co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/unicellab-co

- Industry: Pharmaceuticals
- Headquarters: Uiwang, South Korea
- Website: www.unicellab.com
- Total disclosed funding: $2.2M
- Latest round: Series A (Dec 31, 2019)
- Investors on record: 3

## About

Based in South Korea, and founded in 2018, Unicellab co., ltd., operates as a developer and manufacturer of raw materials used in crystallization medicine. In February 2019, Unicellab co., ltd. raised an undisclosed amount in venture funding from a new investor Yozma Group Korea. As of 2020, Ahn Ji-hoon acts as the CEO of the company.

The company offers APIs (active pharmaceutical ingredients) through research and development of crystal forms of raw materials for various pharmaceutical usages. The company uses co-crystal technology for the development of polycrystalline polymorphs, salts, and amorphous substances.

## Funding rounds

- Series A, Dec 31, 2019, $2.2M — Yozma Group Korea, Laguna Investment, Synergy IB Investment

## Investors

- Yozma Group Korea (https://capitalatlas.ai/funds/yozma-group-korea) — Series A
- Laguna Investment (https://capitalatlas.ai/funds/laguna-investment) — Series A
- Synergy IB Investment (https://capitalatlas.ai/funds/synergy-ib-investment) — Series A